コピー
I'm in my first year at university https://bhuanaagro.com/montelukast-manufacturer-in-pakistan-ekud montelukast and levocetirizine tablets uses Daliresp (roflumilast) for chronic obstructive pulmonary disease climbed 35.2% to $24.0 million, whileツ? $13.1 million, while the newer COPD treatment Tudorza (aclidinium bromide) launched in December last year, recorded sales of $15.9 million. Linzess (linaclotide) was also launched in December for the treatment of both irritable bowel syndrome with constipation and chronic idiopathic constipation and recorded sales of $28.8 million. Viibryd (vilazodone) for major depressive disorder almost doubled to $46.1 million, while sales of the antibiotic Teflaro (ceftaroline fosamil), soared 51.8% to $14.2 million.
TOPに戻る
-
iboard BASIC
-